MCID: HYP006
MIFTS: 51

Hypertensive Heart Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Hypertensive Heart Disease

MalaCards integrated aliases for Hypertensive Heart Disease:

Name: Hypertensive Heart Disease 12 51 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11516
ICD10 32 I11 I11.9 I11.0
ICD9CM 34 402 402.9
UMLS 69 C0152105

Summaries for Hypertensive Heart Disease

Disease Ontology : 12 A heart disease that is caused by high blood pressure.

MalaCards based summary : Hypertensive Heart Disease is related to heart disease and coronary artery anomaly. An important gene associated with Hypertensive Heart Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Pathways in cancer and Colorectal Cancer Metastasis. The drugs Angiotensin II and Irbesartan have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 72 Hypertensive heart disease includes a number of complications of high blood pressure that affect the... more...

Related Diseases for Hypertensive Heart Disease

Diseases related to Hypertensive Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 heart disease 30.6 ACE AGTR1 CD36 CTF1 NPPB NR3C2
2 coronary artery anomaly 30.1 ACE AGTR1 NPPB
3 nephrosclerosis 29.9 ACE AGTR1 NR3C2
4 atrial fibrillation 29.9 ACE AGT AGTR1 NPPB
5 renal dysplasia 29.6 ACE AGT AGTR1
6 diastolic heart failure 29.1 ACE AGT AGTR1 MMP2 NPPB
7 arteries, anomalies of 29.1 ACE AGT AGTR1 MMP9 NPPB
8 hypertension, essential 27.6 ACE AGT AGTR1 CYP11B2 NPPB NPR1
9 dilated cardiomyopathy 27.1 ACE AGT AGTR1 CTF1 CYP11B2 MMP1
10 myocardial infarction 26.8 ACE AGT AGTR1 CTF1 MMP1 MMP2
11 anterolateral myocardial infarction 10.5 ACE NPPB
12 renal artery disease 10.4 ACE AGTR1
13 syndrome of inappropriate antidiuretic hormone 10.4 ACE NPPB
14 pediatric hypertension 10.4 ACE AGT
15 hypertensive nephropathy 10.3 ACE AGTR1
16 aortic valve insufficiency 10.3 ACE NPPB
17 ischemic heart disease 10.3 ACE NPPB
18 fibrosis of extraocular muscles, congenital, 1 10.3
19 hypertrophic cardiomyopathy 10.3
20 renal hypertension 10.3 ACE AGTR1 NPPB
21 idiopathic edema 10.3 ACE NPPB NR3C2
22 systolic heart failure 10.3 ACE NPPB NR3C2
23 keloids 10.2 CD36 MMP1
24 meningococcal infection 10.2 AGT AGTR1
25 conjunctivochalasis 10.2 MMP1 MMP2
26 chronic actinic dermatitis 10.2 MMP1 MMP9
27 squamous cell carcinoma of the hypopharynx 10.2 MMP1 MMP9
28 ischemic colitis 10.2 ACE MMP9
29 hypertrophic scars 10.2 CD36 MMP2
30 renal fibrosis 10.2 AGTR1 CD36 NR3C2
31 chromoblastomycosis 10.2 MMP1 MMP9
32 aortic valve disease 2 10.2 ACE AGT NPPB
33 adult astrocytic tumour 10.2 MMP1 MMP9
34 posterior urethral valves 10.1 ACE AGT AGTR1
35 malignant hypertension 10.1 ACE AGT AGTR1
36 fibromuscular dysplasia 10.1 ACE AGT AGTR1
37 microvascular complications of diabetes 3 10.1 ACE AGT AGTR1
38 oligohydramnios 10.1 ACE AGT AGTR1
39 renal tubular dysgenesis 10.1 ACE AGT AGTR1
40 fibromatosis, gingival, 1 10.1 CD36 MMP1 MMP2
41 ischemic optic neuropathy 10.1 ACE AGT AGTR1
42 end stage renal failure 10.1 ACE AGT AGTR1
43 gingival fibromatosis 10.1 CD36 MMP1 MMP2
44 extracranial arteriovenous malformation 10.1 MMP2 MMP9
45 marfan syndrome 10.1 AGTR1 CD36 MMP2
46 hypoaldosteronism 10.1 ACE CYP11B2
47 focal myositis 10.1 MMP2 MMP9
48 lentigo maligna melanoma 10.1 MMP2 MMP9
49 villous adenocarcinoma 10.1 MMP2 MMP9
50 psammomatous meningioma 10.0 MMP2 MMP9

Comorbidity relations with Hypertensive Heart Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Hypertensive Heart Disease:



Diseases related to Hypertensive Heart Disease

Symptoms & Phenotypes for Hypertensive Heart Disease

MGI Mouse Phenotypes related to Hypertensive Heart Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 AGTR1 MMP2 CD36 ACE AGT CYP11B2
2 homeostasis/metabolism MP:0005376 10.11 AGTR1 MMP1 MMP2 CD36 ACE CTF1
3 growth/size/body region MP:0005378 10.09 AGTR1 MMP2 CD36 ACE CTF1 AGT
4 hematopoietic system MP:0005397 10.01 AGTR1 MMP2 CD36 ACE CYP11B2 NR3C2
5 immune system MP:0005387 9.97 MMP1 AGTR1 MMP2 CD36 ACE AGT
6 adipose tissue MP:0005375 9.95 AGTR1 CD36 ACE CTF1 AGT CYP11B2
7 muscle MP:0005369 9.73 MMP2 CD36 AGT NR3C2 MMP9 NPR1
8 nervous system MP:0003631 9.56 CYP11B2 AGTR1 MMP2 CD36 CTF1 AGT
9 neoplasm MP:0002006 9.55 MMP1 MMP2 ACE MMP9 NPR1
10 renal/urinary system MP:0005367 9.17 AGTR1 CD36 ACE AGT CYP11B2 NR3C2

Drugs & Therapeutics for Hypertensive Heart Disease

Drugs for Hypertensive Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Irbesartan Approved, Investigational Phase 4,Phase 2,Phase 3 138402-11-6 3749
3
Ramipril Approved Phase 4 87333-19-5 5362129
4 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 2,Phase 3
5 Angiotensin Receptor Antagonists Phase 4,Phase 2,Phase 3
6 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3
7 Angiotensinogen Phase 4,Phase 2,Phase 3
8 Antihypertensive Agents Phase 4,Phase 2,Phase 3
9 HIV Protease Inhibitors Phase 4
10
protease inhibitors Phase 4
11
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
12
Atenolol Approved Phase 2, Phase 3 29122-68-7 2249
13
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
14
Enalaprilat Approved Phase 3 76420-72-9 6917719
15 diuretics Phase 3
16 Diuretics, Potassium Sparing Phase 3
17 Hormone Antagonists Phase 3
18 Hormones Phase 3
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
20 Mineralocorticoid Receptor Antagonists Phase 3
21 Mineralocorticoids Phase 3
22 Natriuretic Agents Phase 3
23 Adrenergic Agents Phase 2, Phase 3
24 Adrenergic Antagonists Phase 2, Phase 3
25 Adrenergic beta-1 Receptor Antagonists Phase 2, Phase 3
26 Adrenergic beta-Antagonists Phase 2, Phase 3
27 Anti-Arrhythmia Agents Phase 2, Phase 3
28 Autonomic Agents Phase 2, Phase 3
29 Neurotransmitter Agents Phase 2, Phase 3
30 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 1
31 Sympatholytics Phase 2, Phase 3
32 Pharmaceutical Solutions Phase 2
33
Resveratrol Approved, Experimental, Investigational Phase 1 501-36-0 445154
34 Grape Approved, Nutraceutical Phase 1
35 Antioxidants Phase 1
36 Analgesics Phase 1
37 Analgesics, Non-Narcotic Phase 1
38 Anti-Inflammatory Agents Phase 1
39 Anti-Inflammatory Agents, Non-Steroidal Phase 1
40 Antineoplastic Agents, Phytogenic Phase 1
41 Antirheumatic Agents Phase 1
42 Grape Seed Extract Phase 1
43 Platelet Aggregation Inhibitors Phase 1
44 Protective Agents Phase 1
45 Anthocyanidin Nutraceutical Phase 1
46
Quercetin Experimental, Investigational, Nutraceutical Phase 1 117-39-5 5280343
47
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
48 tannic acid Approved, Nutraceutical
49
Cholecalciferol Approved, Nutraceutical 67-97-0 10883523 5280795 6221
50
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793

Interventional clinical trials:

(show all 16)

# Name Status NCT ID Phase Drugs
1 Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan Unknown status NCT00517322 Phase 4 ramipril;irbesartan
2 Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease Completed NCT00865501 Phase 3 spironolactone;placebo
3 Irbesartan and Atenolol in Hypertensive Heart Disease Completed NCT00389168 Phase 2, Phase 3 Irbesartan;Atenolol
4 Studies of Left Ventricular Dysfunction (SOLVD) Completed NCT00000516 Phase 3 enalapril
5 Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs Recruiting NCT02941705 Phase 2
6 Physiological Effects of Grape Seed Extract in Diastolic Heart Failure Completed NCT01185067 Phase 1 grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
7 Renal Sympathetic Denervation Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study Unknown status NCT01990911 Medical therapy
8 Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure Unknown status NCT00939640
9 Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology Unknown status NCT02672618
10 Asian American Partnerships in Research and Empowerment (AsPIRE) Completed NCT03100812
11 Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients Completed NCT01360476
12 Comparison of CPAP With SOMNOventCR in Patients With Underlying Heart Disease, Combined OSA and CSR Completed NCT00811668
13 Differentiating Hypertrophic Cardiomyopathy From Hypertensive Heart Disease Recruiting NCT03271385
14 REMODEL: Hypertensive Heart Disease Recruiting NCT02670031
15 Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2) Recruiting NCT01942395
16 E_Stethoscope: Portable Digital Auscultation Study on Hypertensive/Hypertensive Heart Disease Patients Active, not recruiting NCT02809040

Search NIH Clinical Center for Hypertensive Heart Disease

Genetic Tests for Hypertensive Heart Disease

Anatomical Context for Hypertensive Heart Disease

MalaCards organs/tissues related to Hypertensive Heart Disease:

38
Heart, Bone, Endothelial, Monocytes, Tongue, Kidney, Bone Marrow

Publications for Hypertensive Heart Disease

Articles related to Hypertensive Heart Disease:

(show top 50) (show all 387)
# Title Authors Year
1
Modulation of cardiac stem cell characteristics by metoprolol in hypertensive heart disease. ( 29449707 )
2018
2
Histamine-2 receptor antagonist famotidine modulates cardiac stem cell characteristics in hypertensive heart disease. ( 29038754 )
2017
3
Cardiac magnetic resonance imaging provides new insight into hypertensive heart disease-a reply. ( 28139052 )
2017
4
Heart Failure WithA Preserved EjectionA Fraction: A Late Stage of Hypertensive Heart Disease. ( 29096816 )
2017
5
Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction. ( 28784688 )
2017
6
A predominance of hypertensive heart disease among patients with cardiac disease in Buea, a semi-urban setting, South West Region of Cameroon. ( 29202813 )
2017
7
Comparison of Pulmonary Venous and Left Atrial Remodeling in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy Versus With Hypertensive Heart Disease. ( 28214001 )
2017
8
Hydrogen sulfide ameliorated L-NAME-induced hypertensive heart disease by the Akt/eNOS/NO pathway. ( 28971696 )
2017
9
Carotid artery intima-media thickness and hypertensive heart disease: a short review. ( 28373912 )
2017
10
MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease. ( 28531963 )
2017
11
Hypertrophic cardiomyopathy and left ventricular hypertrophy in hypertensive heart disease with mildly reduced or preserved ejection fraction: insight from altered mechanics and native T1 mapping. ( 28552325 )
2017
12
A Novel Index of Remodeling in Hypertensive Heart Disease. ( 28847912 )
2017
13
The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease. ( 28535761 )
2017
14
Fragmented QRS: A marker of hypertensive heart disease? ( 28721702 )
2017
15
Reply: Heart Failure With Preserved EjectionA Fraction: A Late Stage of Hypertensive Heart Disease. ( 29096817 )
2017
16
Fibrosis quantification in Hypertensive Heart Disease with LVH and Non-LVH: Findings from T1 mapping and Contrast-free Cardiac Diffusion-weighted imaging. ( 28373647 )
2017
17
NT-pro BNP and plasma-soluble ST2 as promising biomarkers for hypertension, hypertensive heart disease and heart failure in sub-Saharan Africa. ( 29297544 )
2017
18
High fat diet aggravates atrial and ventricular remodeling of hypertensive heart disease in aging rats. ( 28888352 )
2017
19
Autoantibody profiling on a plasmonic nano-gold chip for the early detection of hypertensive heart disease. ( 28630342 )
2017
20
Cardiac magnetic resonance imaging provides a new insight in hypertensive heart disease. ( 28139099 )
2017
21
Regression of Established Cardiac Fibrosis in Hypertensive Heart Disease. ( 28379281 )
2017
22
Hypertensive heart disease beyond left ventricular hypertrophy: are we ready for echocardiographic strain evaluation in everyday clinical practice? ( 29227376 )
2017
23
Shape analysis of hypertrophic and hypertensive heart disease using MRI-based 3D surface models of left ventricular geometry. ( 26766206 )
2016
24
Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy. ( 27142065 )
2016
25
The interplay between renin-angiotensin system activation, abnormal myocardial deformation and neurohumoral activation in hypertensive heart disease: a speckle tracking echocardiography study. ( 27787699 )
2016
26
Case 2/2016 - 76-Year-Old Male with Hypertensive Heart Disease, Renal Tumor and Shock. ( 27305288 )
2016
27
Aircraft, road and railway traffic noise as risk factors for heart failure and hypertensive heart disease-A case-control study based on secondary data. ( 27667192 )
2016
28
Recurrent Syncope: An Unusual Complication of Hypertensive Heart Disease. ( 27448490 )
2016
29
The Relationship Between Left Ventricular Wall Thickness, Myocardial Shortening, and Ejection Fraction in Hypertensive Heart Disease: Insights From Cardiac Magnetic Resonance Imaging. ( 27316563 )
2016
30
Fragmented QRS complexes are a marker of myocardial fibrosis in hypertensive heart disease. ( 27774963 )
2016
31
Obesity and hypertensive heart disease: focus on body composition and sex differences. ( 27956942 )
2016
32
Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness a8Y 15 mm. ( 27368925 )
2016
33
The septal bulge-an early echocardiographic sign in hypertensive heart disease. ( 26850524 )
2016
34
Factors associated to hypertensive heart disease development: a prospective cohort study in Bayamo, Cuba. ( 27571318 )
2016
35
Effect of Renal Sympathetic Denervation on Specific MicroRNAs as an Indicator of Reverse Remodeling Processes in Hypertensive Heart Disease. ( 26916982 )
2016
36
SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH. ( 27753836 )
2016
37
Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost Effectiveness Analysis. ( 27797437 )
2016
38
JS ISH-ESH-2 UPDATE ON THE DETECTION AND FOLLOW-UP OF EARLY HYPERTENSIVE HEART DISEASE. ( 27642917 )
2016
39
Prognostic Implications of LV Strain RiskA ScoreA inA Asymptomatic Patients WithA Hypertensive Heart Disease. ( 27344417 )
2016
40
Cardiac Fibrosis in Aortic Stenosis and Hypertensive Heart Disease Assessed by Magnetic Resonance T1 Mapping. ( 28238233 )
2016
41
Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes. ( 27260191 )
2016
42
Electrocardiography for Assessment of Hypertensive Heart Disease: A New Role for an Old Tool. ( 27160048 )
2016
43
JS ISH-ESH-2 UPDATE ON THE DETECTION AND FOLLOW-UP OF EARLY HYPERTENSIVE HEART DISEASE. ( 27754006 )
2016
44
SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH. ( 27642889 )
2016
45
Galectin-3 and Hypertensive Heart Disease. ( 26693838 )
2015
46
Comparison of right ventricular contractile abnormalities in hypertrophic cardiomyopathy versus hypertensive heart disease using two dimensional strain imaging: a cross-sectional study. ( 26245470 )
2015
47
Safety of digoxin use in patients with hypertensive heart disease and atrial fibrillation. ( 26039531 )
2015
48
The importance of left ventricular geometry in hypertensive heart disease. ( 25915870 )
2015
49
Macrophages dictate the progression and manifestation of hypertensive heart disease. ( 26539962 )
2015
50
Association of impaired left ventricular twisting-untwisting with vascular dysfunction, neurohumoral activation and impaired exercise capacity in hypertensive heart disease. ( 26443037 )
2015

Variations for Hypertensive Heart Disease

Expression for Hypertensive Heart Disease

Search GEO for disease gene expression data for Hypertensive Heart Disease.

Pathways for Hypertensive Heart Disease

Pathways related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1 12.59 AGTR1 MMP1 MMP2 MMP9
2 11.93 MMP1 MMP2 MMP9
3
Show member pathways
11.9 AGT CTF1 NPPB
4 11.68 CD36 MMP1 MMP2 MMP9
5
Show member pathways
11.65 MMP1 MMP2 MMP9
6 11.5 MMP1 MMP2 MMP9
7
Show member pathways
11.41 MMP1 MMP2 MMP9
8 11.37 MMP1 MMP2 MMP9
9 11.27 ACE AGT AGTR1 NPR1
10 11.08 MMP1 MMP2 MMP9
11 10.97 MMP2 MMP9
12 10.95 AGT CTF1
13
Show member pathways
10.92 ACE AGT AGTR1 CYP11B2 NR3C2
14 10.83 MMP1 MMP2
15 10.79 ACE MMP2 MMP9
16 10.76 ACE CD36 MMP2 MMP9
17 10.73 MMP1 MMP9

GO Terms for Hypertensive Heart Disease

Cellular components related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ACE AGT CTF1 MMP1 MMP2 MMP9
2 extracellular space GO:0005615 9.17 ACE AGT CD36 CTF1 MMP2 MMP9
3 receptor complex GO:0043235 9.13 CD36 NPR1 NR3C2

Biological processes related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 9.82 AGT AGTR1 CD36
2 negative regulation of cell growth GO:0030308 9.81 AGT NPPB NPR1
3 cell surface receptor signaling pathway GO:0007166 9.8 AGT CD36 CTF1 NPPB NPR1
4 kidney development GO:0001822 9.79 ACE AGT AGTR1
5 negative regulation of angiogenesis GO:0016525 9.78 AGT NPPB NPR1
6 extracellular matrix disassembly GO:0022617 9.74 MMP1 MMP2 MMP9
7 collagen catabolic process GO:0030574 9.73 MMP1 MMP2 MMP9
8 positive regulation of protein tyrosine kinase activity GO:0061098 9.67 ACE AGT
9 blood vessel remodeling GO:0001974 9.66 ACE AGT
10 endodermal cell differentiation GO:0035987 9.66 MMP2 MMP9
11 positive regulation of epidermal growth factor receptor signaling pathway GO:0045742 9.65 AGT MMP9
12 cGMP biosynthetic process GO:0006182 9.65 NPPB NPR1
13 positive regulation of reactive oxygen species metabolic process GO:2000379 9.65 AGT AGTR1 CD36
14 nitric oxide mediated signal transduction GO:0007263 9.64 AGT CD36
15 positive regulation of cellular protein metabolic process GO:0032270 9.64 AGT AGTR1
16 low-density lipoprotein particle remodeling GO:0034374 9.63 AGT AGTR1
17 regulation of vasoconstriction GO:0019229 9.63 ACE AGT AGTR1
18 positive regulation of urine volume GO:0035810 9.62 NPPB NPR1
19 angiotensin maturation GO:0002003 9.61 ACE AGT
20 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.61 AGT MMP2 MMP9
21 regulation of vascular permeability GO:0043114 9.6 NPPB NPR1
22 receptor guanylyl cyclase signaling pathway GO:0007168 9.59 NPPB NPR1
23 body fluid secretion GO:0007589 9.58 NPPB NPR1
24 positive regulation of cholesterol esterification GO:0010873 9.58 AGT AGTR1
25 positive regulation of NAD(P)H oxidase activity GO:0033864 9.55 AGT AGTR1
26 renin-angiotensin regulation of aldosterone production GO:0002018 9.54 AGT AGTR1
27 regulation of blood vessel size GO:0050880 9.54 AGT NPPB NPR1
28 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.52 AGT AGTR1
29 regulation of renal sodium excretion GO:0035813 9.51 AGT AGTR1
30 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.5 AGT AGTR1 CD36
31 regulation of renal output by angiotensin GO:0002019 9.49 ACE AGT
32 regulation of blood pressure GO:0008217 9.46 ACE AGT NPPB NPR1
33 positive regulation of renal sodium excretion GO:0035815 9.43 AGT NPPB NPR1
34 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.13 ACE AGT AGTR1
35 regulation of blood vessel diameter GO:0097746 8.92 ACE AGTR1 NPPB NPR1

Molecular functions related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.72 ACE MMP1 MMP2 MMP9 NR3C2
2 peptidase activity GO:0008233 9.67 ACE MMP1 MMP2 MMP9
3 metalloendopeptidase activity GO:0004222 9.43 MMP1 MMP2 MMP9
4 endopeptidase activity GO:0004175 9.33 ACE MMP1 MMP9
5 metallopeptidase activity GO:0008237 9.26 ACE MMP1 MMP2 MMP9
6 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1

Sources for Hypertensive Heart Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....